Skip to content
Screener

Lantheus Holdings LNTH Reportable — Research And Development Expense

Similar metrics at other companies

Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Alumis Inc. logo
ALMSSingle Reportable — Research And Development Expense
$81.54M-15.6%
Napco Security Technologies logo
NSSCSingle Reportable — Research And Development Expense
$400K+22.0%
Capricor Therapeutics logo
CAPRSingle Reportable — Research And Development Expense
$27.38M+44.7%
Plug Power logo
PLUGSingle Reportable — Research And Development Expense
$12.11M-30.2%
Dogwood Therapeutics logo
DWTXSingle Reportable — Research And Development Expense
$2.67M+9.6%

Other financials

Income statement

See full
Revenue$388.2M+2.7%
Gross profit$241.9M+0.4%
Operating income$100.2M+13.9%
Net income$75.0M-4.7%
EPS (diluted)$1.11-0.9%

Balance sheet

See full
Cash & equivalents$595.0M-14.7%
Total debt$626.8M+1.5%
Total equity$1.3B+12.4%
Total assets$2.4B+14.1%

Cash flow

See full
Operating cash flow$92.2M+5.9%
CapEx$2.3M-70.7%
Free cash flow$89.9M+13.5%

Valuation

See full
Market cap$6.6B+83.8%
Enterprise value$6.63B+88.9%
P/E24×+11.3×
P/S4.2×+1.9×

Profitability

See full
Gross margin60.1%-3.6pp
Operating margin19.4%-9.4pp
Net margin17.7%-0.9pp
FCF margin24.9%-6.6pp

Returns & leverage

See full
Return on equity22.2%-3.6pp
Debt / equity0.5×-0.1×
Current ratio3.1×-1.2×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Lantheus Holdings’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336795
(in thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Program third-party research and development expenses$8,475$8,938$20,263$17,367
Other research and development expenses(1)29,72736,55157,31864,436
Total research and development expenses$38,202$45,489$77,581$81,803

Item 1. Financial Statements

FAQ

What is Lantheus Holdings's reportable — research and development expense?
Lantheus Holdings (LNTH) reported reportable — research and development expense of $38.2M in Q2 2026.
How has Lantheus Holdings's reportable — research and development expense changed year-over-year?
Lantheus Holdings's reportable — research and development expense decreased by 16.0% year-over-year, from $45.49M to $38.2M.
What is the long-term trend for Lantheus Holdings's reportable — research and development expense?
Over 3 years (2022 to 2025), Lantheus Holdings's reportable — research and development expense has grown at a -17.1% compound annual growth rate (CAGR), from $311.68M to $177.31M.
What does reportable — research and development expense mean?
This metric represents the total aggregate expenditure dedicated to research and development activities within the reportable business segment. It reflects the company's overall financial commitment to discovering, developing, and refining diagnostic and therapeutic products to maintain market competitiveness. Analyzing this total spend relative to revenue growth helps investors evaluate the effectiveness of the company's innovation strategy and long-term value creation.

Ask your AI about Lantheus Holdings's reportable — research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude